Meanwhile, results of the survival analysis showed that there was no significant difference in progression-free survival between patients in Xp11.2 translocation RCC group and those in the TFE3-positive non-Xp11.2 translocation RCC group (p=0.9607, Figure 4B). The gene discussed is TFE3; the disease is renal cell carcinoma.